The new issue of Px Wire
, AVAC's quarterly newsletter on HIV prevention research, is now available and includes a new infographic on the pathways for developing long-acting injectable antiretrovirals for treatment and prevention.
Click here to download the issue and infographic.
In this issue, we review the research on long-acting injectable antiretrovirals for treatment in HIV-positive people and PrEP in HIV-negative people. The pathways for developing these products have key similarities as well as differences—and as the same drugs advance for treatment and PrEP, it will be key to communicate these. We hope this issue of Px Wire
is a start.
Advocates who want to learn more can listen to a recent webinar
on long-acting injectables, and look for a Q&A document at avac.org
in the near future.
This quarter’s issue also explores progress in implementing oral PrEP. It's been nearly 24 months since the US Food and Drug Administration approved daily oral TDF/FTC (Truvada) as PrEP. In that time we've seen an increasing number of people begin to view the strategy as an important niche intervention that could save lives and should be promoted more widely. For more information on PrEP, visit www.prepwatch.org
Additional resources including the Px Wire
archive, information about subscribing, reprint requests and bulk orders can be found at www.avac.org/pxwire
As always, we welcome your questions and comments at firstname.lastname@example.org